Results 81 to 90 of about 17,850,454 (351)

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

open access: yesNew England Journal of Medicine
BACKGROUND The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk.
Darren K. McGuire   +17 more
semanticscholar   +1 more source

Representation of Sickle Cell Disease Patients in Pediatric and Adult Care: What We Discovered Using Informatics for Integrating Biology and the Bedside (i2b2) Data

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Transitioning from pediatric to adult care is a high‐risk period for individuals with sickle cell disease (SCD). An initial observation at one academic medical center suggested a sex‐based disparity in clinic populations, prompting a national investigation.
Laurie J. Duckworth   +5 more
wiley   +1 more source

Cardiovascular risk and obesity [PDF]

open access: yesDiabetology & Metabolic Syndrome, 2019
This is an overview of the mechanisms of obesity and its relation to cardiovascular risks, describing the available treatment options to manage this condition.The pathogenesis of obesity includes the balance between calories consumed and energy expenditure followed by the maintenance of body weight.
C. Cercato, F. A. Fonseca
openaire   +3 more sources

Effect of DFPP on Ferroptosis in Peripheral Blood CD14+ Monocytes of Hyperlipidemic Patients Involving the ACSL4/LPCAT3/ALOX5 Pathway

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid‐lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non‐drug treatment using double‐filtration plasmapheresis (DFPP) on CD14+
Yun Cheng   +3 more
wiley   +1 more source

Screening families of patients with premature coronary heart disease to identify avoidable cardiovascular risk: a cross-sectional study of family members and a general population comparison group [PDF]

open access: yes, 2010
<b>Background:</b> Primary prevention should be targeted at individuals with high global cardiovascular risk, but research is lacking on how best to identify such individuals in the general population.
Pell, A.C.H.   +14 more
core   +1 more source

Chronic kidney disease progression in patients with previous type 2 diabetes and/or hypertension: a population-based cohort study from primary care in Spain

open access: yesBMJ Open
Objectives To evaluate whether between hypertension and type 2 diabetes (T2D)—established drivers of chronic kidney disease (CKD) progression—one might be more strongly associated with CKD progression than the other.Design Cohort study using a primary ...
David Vizcaya   +6 more
doaj   +1 more source

Microalbuminuria and cardiovascular risk [PDF]

open access: yesAmerican Journal of Hypertension, 2004
Microalbuminuria is a marker for generalized vascular dysfunction. Its prevalence in United States and European general population surveys ranges from 6% to 10%. Increased risk for cardiovascular morbidity and mortality begins with albumin excretion rates that are well within normal limits.
Karalliedde, J, Viberti, G
openaire   +3 more sources

The Impact of Tenapanor on Body Composition and Blood Pressure in Peritoneal Dialysis Patients: A Pilot Study

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Instruction Tenapanor potentially affects fluid volume and blood pressure. This study explored its effects on these parameters in patients undergoing peritoneal dialysis (PD). Methods We conducted a single‐arm, prospective observational study that enrolled 10 patients on PD with hyperphosphatemia who were newly initiated on tenapanor.
Shun Yoshida   +11 more
wiley   +1 more source

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies

open access: yesAmerican Heart Journal Plus, 2022
Study objective: This systematic review and meta-analysis aimed to assess the efficacy and safety profile of treatment with inclisiran, a drug that has been recently approved by the United States Food and Drug Administration (FDA) and the European ...
Arrigo F.G. Cicero   +4 more
doaj   +1 more source

Testosterone and cardiovascular risk [PDF]

open access: yesThe Lancet Diabetes & Endocrinology, 2015
1 Health Canada. Information update: possible cardiovascular problems associated with testosterone products. http://healthycanadians. gc.ca/recall-alert-rappel-avis/hc-sc/2014/ 40587a-eng.php (accessed July 15, 2014). 2 European Medicines Agency. No consitent evidence of an increased risk of heart problems with testosterone medicines.
C Mary, Schooling, Gabriel M, Leung
openaire   +2 more sources

Home - About - Disclaimer - Privacy